Current Oncology (Feb 2024)

Quality of Life Longitudinal Evaluation in Prostate Cancer Patients from Radiotherapy Start to 5 Years after IMRT-IGRT

  • Angelo Maggio,
  • Tiziana Rancati,
  • Marco Gatti,
  • Domenico Cante,
  • Barbara Avuzzi,
  • Cinzia Bianconi,
  • Fabio Badenchini,
  • Bruno Farina,
  • Paolo Ferrari,
  • Tommaso Giandini,
  • Giuseppe Girelli,
  • Valeria Landoni,
  • Alessandro Magli,
  • Eugenia Moretti,
  • Edoardo Petrucci,
  • Paolo Salmoiraghi,
  • Giuseppe Sanguineti,
  • Elisa Villa,
  • Justyna Magdalena Waskiewicz,
  • Alessia Guarneri,
  • Riccardo Valdagni,
  • Claudio Fiorino,
  • Cesare Cozzarini

DOI
https://doi.org/10.3390/curroncol31020062
Journal volume & issue
Vol. 31, no. 2
pp. 839 – 848

Abstract

Read online

Purpose: The purpose of this study is to study the evolution of quality of life (QoL) in the first 5 years following Intensity-modulated radiation therapy (IMRT) for prostate cancer (PCa) and to determine possible associations with clinical/treatment data. Material and methods: Patients were enrolled in a prospective multicentre observational trial in 2010-2014 and treated with conventional (74–80 Gy, 1.8–2 Gy/fr) or moderately hypofractionated IMRT (65–75.2 Gy, 2.2–2.7 Gy/fr). QoL was evaluated by means of EORTC QLQ-C30 at baseline, at radiation therapy (RT) end, and every 6 months up to 5 years after IMRT end. Fourteen QoL dimensions were investigated separately. The longitudinal evaluation of QoL was analysed by means of Analysis of variances (ANOVA) for multiple measures. Results: A total of 391 patients with complete sets of questionnaires across 5 years were available. The longitudinal analysis showed a trend toward the significant worsening of QoL at RT end for global health, physical and role functioning, fatigue, appetite loss, diarrhoea, and pain. QoL worsening was recovered within 6 months from RT end, with the only exception being physical functioning. Based on ANOVA, the most impaired time point was RT end. QoL dimension analysis at this time indicated that acute Grade ≥ 2 gastrointestinal (GI) toxicity significantly impacted global health, physical and role functioning, fatigue, appetite loss, diarrhoea, and pain. Acute Grade ≥ 2 genitourinary (GU) toxicity resulted in lower role functioning and higher pain. Prophylactic lymph-nodal irradiation (WPRT) resulted in significantly lower QoL for global health, fatigue, appetite loss, and diarrhoea; lower pain with the use of neoadjuvant/concomitant hormonal therapy; and lower fatigue with the use of an anti-androgen. Conclusions: In this prospective, longitudinal, observational study, high radiation IMRT doses delivered for PCa led to a temporary worsening of QoL, which tended to be completely resolved at six months. Such transient worsening was mostly associated with acute GI/GU toxicity, WPRT, and higher prescription doses.

Keywords